Guide to Psychedelic Integration Therapy in Washington DC

Psychedelic Integration Therapy in Washington DC | Ketamine & Psilocybin

By Joseph W. LaFleur Jr., LICSW, MBA, SEP, C-PATP  |  Clinical Director, District Counseling and Psychotherapy

Confidentiality Notice: This page provides educational information only and does not establish a therapist-client relationship. For a confidential consultation, call District Counseling and Psychotherapy at 202-641-5335.

General Information Deeper Dive for Healthcare Workers

Your Guide to Psychedelic Integration Therapy in Washington DC

This guide explores psychedelic treatment options and integration therapy in Washington DC. It shows how professional support can help you process your psychedelic experiences and heal from trauma.

Meet Joseph LaFleur — Certified Psychedelic Assisted Therapy Provider

Joseph LaFleur specializes in psychedelic integration therapy. He helps people process their psychedelic experiences at District Counseling and Psychotherapy in Washington DC. Joseph is certified, and he uses his training to help clients recover and grow.

His qualifications:

• Certified Psychedelic-Assisted Therapy — Integrative Psychiatric Institute
• Somatic Experiencing Therapy — Somatic Experiencing Trauma Institute (SETI)
• Psychoanalytic Psychotherapy — Washington Baltimore Center for Psychoanalysis
• Licensed Independent Clinical Social Worker (LICSW)

Joseph's training makes him one of the leading psychedelic integration therapists in Washington DC.

What Is Psychedelic Integration Therapy?

Psychedelic integration therapy helps you understand insights from your psychedelic experiences. Your therapist gives you a safe space to explore your feelings and build practical strategies for growth. Without integration, valuable experiences can fade away without leading to lasting change.

Why Integration Therapy Matters

As attitudes toward psychedelics change and more research comes out, more people want support to understand their experiences. This therapy bridges the gap between the experience itself and long-term change. It is valuable for people working through trauma, depression, anxiety, and questions about meaning and purpose.

Ketamine-Assisted Therapy and Suicidal Thoughts

Ketamine-assisted therapy (KAP) has shown real promise in reducing suicidal thoughts, especially for people whose depression has not responded to other treatments. It can bring quick relief, often within hours. This fast response matters because it opens a window for people to engage more fully with ongoing mental health care and can offer renewed hope.

MDMA and PTSD

MDMA-assisted therapy is one of the most promising new treatments for severe PTSD. It is not yet FDA-approved, and MDMA remains a controlled substance available mainly through research studies. Large clinical trials have shown that many participants no longer met the criteria for PTSD after treatment. If you have had this experience in a research or legal setting, integration therapy can help you process what came up.

Psilocybin and Depression

Psilocybin therapy is being studied as a treatment for depression that has not responded to other approaches. Research from major universities shows that it can bring meaningful mood improvement, sometimes after just one or two guided sessions. Psilocybin remains a controlled substance in most places. Integration therapy for people who have already had a psilocybin experience is legal and available.

Who Can Benefit?

Psychedelic integration therapy can help:

• People who took part in legal clinical trials
• People who attended legal ceremonies or had personal psychedelic experiences
• Anyone preparing for a future psychedelic session
• People dealing with lingering effects from past use

Preparing for an Experience

Good preparation makes a real difference. It includes setting a clear intention, talking through fears or worries, thinking about the right setting and support, and reviewing any health risks with a professional beforehand.

Integrating the Experience Afterward

Integration is an ongoing process, not a single conversation. In the days and weeks right after an experience, many people feel open and emotionally sensitive. In the months that follow, the work shifts to holding onto insights while returning to everyday life. Over time, the goal is for new perspectives to become a lasting part of how you think, feel, and act. Helpful tools include talking it through with a therapist, journaling, mindfulness, movement, and connecting with others who understand.

The Role of the Therapist

A good integration therapist understands both traditional mental health care and the unique territory of psychedelic experiences. This helps you make sense of complex emotions, work through spiritual or unusual insights, and turn what you learned into everyday, practical change.

A Note on Legal Status

Ketamine can legally be given in medical settings. MDMA and psilocybin remain controlled substances in most places and are generally available only through approved research. District Counseling and Psychotherapy provides integration therapy — talking through and processing your experience — and does not supply, administer, or facilitate access to any controlled substance.

Conclusion

Psychedelic integration therapy is a valuable process for anyone who wants to understand and use a psychedelic experience for real, lasting growth. With Joseph LaFleur's guidance at District Counseling and Psychotherapy in Washington DC, you can navigate this journey with expert, compassionate support.

Frequently Asked Questions

What is psychedelic integration therapy?

It helps you take the insights and feelings from a psychedelic experience and turn them into lasting change in your daily life. Without this work, even powerful experiences can fade without creating real change.

Who can benefit from this therapy in Washington DC?

People who joined legal clinical trials, attended legal ceremonies, had a personal experience, are preparing for a future session, or are still processing effects from the past. It is especially helpful for trauma, depression, anxiety, and life-meaning questions.

Are ketamine, MDMA, and psilocybin legal?

Ketamine can be legally given in medical settings. MDMA and psilocybin remain controlled substances and are mainly available through research studies. District Counseling and Psychotherapy offers integration therapy only and does not provide or facilitate access to controlled substances.

What are Joseph LaFleur's qualifications?

He is a Certified Psychedelic Assisted Therapy Provider, trained in Somatic Experiencing and Psychoanalytic Psychotherapy, and is a Licensed Independent Clinical Social Worker (LICSW).

---

Ready to integrate your experience?
Call 202-641-5335 or visit districtcounseling.com to schedule a consultation.

Understanding Psychedelic Therapies: A Clinical Overview

This section reviews the neuropharmacology and clinical evidence behind ketamine-, MDMA-, and psilocybin-assisted approaches, and the role of structured integration therapy in sustaining treatment gains. It is intended for clinicians, referring providers, and other healthcare professionals evaluating psychedelic-adjacent care pathways for their patients.

Ketamine-Assisted Therapy: Mechanism of Action

Ketamine functions primarily as a non-competitive NMDA receptor antagonist, modulating glutamatergic signaling implicated in mood regulation and synaptic plasticity. NMDA receptor blockade triggers a downstream cascade — including AMPA receptor activation and increased BDNF (brain-derived neurotrophic factor) signaling — that promotes synaptogenesis and rapid neuroplastic remodeling. This mechanism is distinct from monoaminergic antidepressants and underlies ketamine's characteristically rapid antidepressant response, often within hours rather than weeks.

Ketamine and Suicidality

Clinical studies consistently demonstrate rapid reduction in suicidal ideation following ketamine administration, frequently within hours of dosing, independent of overall antidepressant response trajectory. This rapid effect is clinically significant for acute risk management, providing a window in which patients can engage more fully with concurrent psychotherapeutic and psychiatric care. Ketamine's safety profile is favorable when administered with appropriate screening, dosing protocols, and cardiovascular monitoring, though careful attention to dissociative effects and abuse potential is warranted in ongoing treatment planning.

Neuroplasticity as a Therapeutic Substrate

Neuroplasticity — the brain's capacity to reorganize synaptic connections in response to experience — is central to recovery from depression and trauma-related conditions. Ketamine-induced neuroplastic windows create a time-limited period of heightened synaptic flexibility during which new cognitive and emotional patterns are more readily encoded. This is the clinical rationale for pairing pharmacological intervention with concurrent or closely timed integration therapy: the neuroplastic window provides an opportunity, but psychotherapeutic processing is what determines whether new patterns are consolidated into durable change.

MDMA-Assisted Therapy: Neurobiological Basis

MDMA acts primarily by promoting the release of serotonin, dopamine, and norepinephrine while also increasing circulating oxytocin. Functionally, this produces transient downregulation of amygdala reactivity alongside increased activity in regions associated with self-referential processing and fear extinction, allowing traumatic material to be revisited with reduced physiological threat response. This altered fear-processing state is theorized to widen the window of tolerance during trauma-focused psychotherapy, facilitating engagement with material that would otherwise be too dysregulating to process safely.

Phase 3 trials conducted by the Multidisciplinary Association for Psychedelic Studies (MAPS) reported that approximately 67% of participants receiving MDMA-assisted therapy no longer met diagnostic criteria for PTSD post-treatment, compared to 32% in the placebo-with-therapy arm. The FDA has granted MDMA-assisted therapy for PTSD Breakthrough Therapy designation, though full approval has faced regulatory setbacks, and MDMA remains a Schedule I substance available primarily through research protocols.

Psilocybin-Assisted Therapy: Receptor Dynamics

Psilocybin is dephosphorylated in vivo to its active metabolite, psilocin, which acts as a partial agonist at serotonin 5-HT2A receptors, with additional affinity for 5-HT1A and 5-HT2C sites. 5-HT2A agonism is associated with altered cortical connectivity patterns, including disruption of default mode network activity — a pattern hypothesized to underlie the acute alterations in self-referential processing and rigid cognitive patterning characteristic of depressive states.

Neuroplasticity and Neurogenesis

Preclinical research indicates psilocybin promotes dendritic spine formation and may support hippocampal neurogenesis, mechanisms consistent with its capacity to facilitate durable shifts in mood and cognitive flexibility. Clinical trials from Johns Hopkins University and Imperial College London have reported rapid and sustained antidepressant effects in major depressive disorder, with benefit frequently observed after one or two supported dosing sessions and persistence of effect reported at multi-month follow-up in several cohorts. Psilocybin remains a Schedule I substance in most jurisdictions; clinical access remains largely limited to research and expanded-access frameworks.

Integration Therapy as the Mechanism of Durable Change

Across all three agents, the acute pharmacological and neuroplastic effects are time-limited; sustained clinical benefit depends substantially on structured integration work following the dosing experience. Integration therapy addresses cognitive consolidation of insights, affective processing of material that surfaces during or after sessions, somatic processing of bodily sensations and trauma activation, and behavioral translation of insight into concrete life change. Research published in the Journal of Psychopharmacology associates structured integration support with improved and more durable therapeutic outcomes relative to dosing sessions without integration support.

Scope of Practice and Referral Considerations

District Counseling and Psychotherapy provides preparation and integration psychotherapy and does not administer, prescribe, or facilitate access to controlled substances. For ketamine care specifically, the practice coordinates with licensed medical providers responsible for screening, dosing, and monitoring. Referring clinicians considering integration therapy as an adjunct to ketamine treatment, or supporting patients with prior legal or research-based MDMA or psilocybin exposure, may contact the practice directly to discuss coordinated care.

---

Considering a referral or coordinated care?
Call 202-641-5335 or visit districtcounseling.com.

Joseph W. LaFleur Jr., LICSW, MBA, SEP, C-PATP is the Clinical Director of District Counseling and Psychotherapy in Washington, DC. He is a Certified Psychedelic Assisted Therapy Provider (C-PATP) and specializes in men's mental health, LGBTQ+ affirming care, somatic healing, and psychedelic-assisted therapy integration. Licensed in DC, MD, VA, NJ, and NY.